Business
Cardax Reports Q3 2017 Results
Cardax Reports Q3 2017 Results.
About this update from Cardax Inc
[{"type":"text","content":"\n\n\n\nCardax Reports Q3 2017 Results\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prnsbls{\nBORDER-LEFT:black 1pt solid\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n.prnsbbs{\nBORDER-BOTTOM:black 1pt solid\n}\n.prnvab{\nVERTICAL-ALIGN: BOTTOM\n}\n.prnrbrs{\nBORDER-RIGHT:black 1pt solid\n}\n.prnpl6{\nPADDING-LEFT:0.50em\n}\n.prnsbts{\nBORDER-TOP:black 1pt solid\n}\n.prnpr6{\nPADDING-RIGHT:0.50em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n\n\n\n\n\n\nCardax Reports Q3 2017 Results\nRevenues Up Nearly 5 Times from Q2 2017\nPR Newswire\nHONOLULU, Nov. 14, 2017\n\n\n\nHONOLULU, Nov. 14, 2017 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced strong ZanthoSyn® revenues of approximately $322,000 for the third quarter of 2017 — up nearly 5 times from the second quarter of 2017, as reported in the Company's Form 10-Q filed today.\n\nThese results include the initial national stocking orders of ZanthoSyn from General Nutrition Corporation (\"GNC\") for its more than 3,200 corporate stores across the US, as well as increased same-store sales of ZanthoSyn in Hawaii GNC stores.\n\nManagement also highlighted the major milestones achieved this year that have helped drive increasing sales:\n\n\nZanthoSyn national rollout to more than 3,200 GNC corporate stores in the US\nRobust physician outreach and education in Hawaii\nIncreasing consumer awareness in Hawaii\nBreakthrough anti-aging research results reported with research collaborator University of Hawaii\nCardax astaxanthin compound CDX-085 chosen as top anti-aging prospect by NIH\nApproximately $4 million in new capital raised to fund these efforts\n\"We are very pleased to see a strong trend of accelerating sales of ZanthoSyn,\" said David G. Watumull, Cardax President and CEO. \"We believe it reflects our successful sales and marketing strategy focused on increasing physician and consumer awareness of the anti-inflammatory health benefits of ZanthoSyn. Additionally, the increased capital will fuel further company growth and advance deve...